Evidence map›Paper›PMID 22801247›Full record

Trial reportJournal of investigative medicine : the official publication of the American Federation for Clinical Research2012

Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.

Ildiko Lingvay, Erin D Roe, Jonathan Duong, David Leonard, Lidia S Szczepaniak

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Combination Therapies for Nonalcoholic Fatty Liver Disease.Journal of personalized medicine · 2022
    Review
  3. Article
  4. Article
  5. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ildiko LingvayDivision of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8857, USA. ildiko.lingvay@utsouthwestern.edu
Erin D Roe
Jonathan Duong
David Leonard
Lidia S Szczepaniak
The University of Texas Southwestern Medical Center · US

Funding

NORTH AND CENTRAL TEXAS CTSA FOR PEDIATRIC RESEARCHUL1RR024982 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2007 to 2011
$27.9M
Role of Pancreatic Triglycerides in Beta-cell DysfunctionK23RR024470 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI LINGVAY, ILDIKO · 2007 to 2011
$755k
Sphingosine 1-phosphate and the pulmonary vasculature: Implications for ALIK08HL083101 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCVERRY, BRYAN J · 2007 to 2011
$625k
NCRR NIH HHS 3UL1 RR024982-05S1NCRR NIH HHS K23 RR024470NCRR NIH HHS K23RR024470NCRR NIH HHS UL1 RR024982NHLBI NIH HHS K08 HL083101
6 · The paper itself

Abstract

backgroundHyperinsulinemia has been associated with hepatic fat deposition and ensuing insulin resistance. It is unknown if treatment with exogenous insulin in patients with type 2 diabetes, who are most prone to hepatic fat accumulation, would promote the occurrence or worsening of nonalcoholic fatty liver disease.

methodsPatients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin. Hepatic triglyceride content (HTC)-measured by magnetic resonance spectroscopy, serum lipids, glucose, liver function tests, and inflammatory and thrombotic biomarkers were followed for a median of 31 months.

resultsThe 45% decline in HTC during the lead-in period persisted through the follow-up period with no difference between treatment groups at the end of the study (5.26 ± 4.21% in the triple oral therapy vs 7.47 ± 7.40% for insulin/metformin), whereas glycemic control was comparable.

conclusionsImprovements in HTC with initial insulin/metformin therapy persisted through the median 31-month follow-up period regardless of the treatment. More importantly, insulin-based treatment did not appear to promote or worsen nonalcoholic fatty liver disease.

Indexed as

Disease ProgressionAdministration, OralAdultAgedDiabetes Mellitus, Type 2Fatty LiverFemaleFollow-Up StudiesGlyburideHumansHypoglycemic AgentsInsulinLiverMaleMetforminMiddle AgedGlyburideHypoglycemic AgentsInsulinMetforminPioglitazoneThiazolidinedionesTriglycerides

Identifiers

PMID22801247
PMCPMC3448864
OpenAlexW184067429

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.